Insider Selling: Edwards Lifesciences Corp. CEO Sells 29,500 Shares of Stock (EW)
Edwards Lifesciences Corp. (NYSE:EW) CEO Michael Mussallem sold 29,500 shares of the company’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $72.63, for a total transaction of $2,142,585.00. Following the completion of the transaction, the chief executive officer now directly owns 263,850 shares of the company’s stock, valued at approximately $19,163,426. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
EW has been the subject of a number of recent research reports. Analysts at RBC Capital reiterated a “hold” rating on shares of Edwards Lifesciences Corp. in a research note to investors on Thursday, October 3rd. They now have a $75.00 price target on the stock. Separately, analysts at Stifel Nicolaus raised their price target on shares of Edwards Lifesciences Corp. from $81.00 to $82.00 in a research note to investors on Thursday, October 3rd. They now have a “buy” rating on the stock. Finally, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Edwards Lifesciences Corp. in a research note to investors on Tuesday, September 10th. They now have a $90.00 price target on the stock. One analyst has rated the stock with a sell rating, ten have issued a hold rating and twelve have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $79.13.
Edwards Lifesciences Corp. (NYSE:EW) traded up 1.18% during mid-day trading on Thursday, hitting $73.74. The stock had a trading volume of 863,520 shares. Edwards Lifesciences Corp. has a 52-week low of $62.34 and a 52-week high of $94.98. The stock’s 50-day moving average is $71.27 and its 200-day moving average is $71.02. The company has a market cap of $8.279 billion and a price-to-earnings ratio of 21.30.
Edwards Lifesciences Corp. (NYSE:EW) last announced its earnings results on Thursday, July 25th. The company reported $0.82 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.76 by $0.06. The company had revenue of $517.20 million for the quarter, compared to the consensus estimate of $514.59 million. During the same quarter last year, the company posted $0.57 earnings per share. Edwards Lifesciences Corp.’s revenue was up 7.3% compared to the same quarter last year. Analysts expect that Edwards Lifesciences Corp. will post $3.07 EPS for the current fiscal year.
Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.